Healthcare / Medical DevicesShanghai
$42.25
+1.45 (+3.55%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $71.0M · quality 81.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.4B
P/E
38.1x
↑EV/EBITDA
23.7x
↑ROE
13.8%
↑Gross Margin
78.7%
↑Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.5%
FCF CAGR
-3.3%
FCF margin
19.0%
FCF / Net income
0.68x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $351.1M · net income $98.7M · FCF $66.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $351.1M | $351.1M | $321.9M | $275.0M | $239.9M |
| Net Income | $98.7M | $98.7M | $88.4M | $75.5M | $75.7M |
| EBITDA | $133.4M | $133.4M | $121.7M | $106.0M | $101.5M |
| EPS | 1.21 | 1.21 | 1.09 | 0.93 | 0.93 |
| Gross Margin | 78.7% | 78.7% | 80.0% | 81.2% | 81.5% |
| Operating Margin | 35.8% | 35.8% | 37.9% | 35.9% | 35.5% |
| Net Margin | 28.1% | 28.1% | 27.5% | 27.5% | 31.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.12 | 0.12 | 0.07 | 0.07 | 0.07 |
| Current Ratio | 4.31 | 4.31 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $66.7M | $66.7M | $92.9M | $71.0M | $73.8M |
| Returns | |||||
| ROE | 13.8% | 13.8% | 13.9% | 12.9% | 13.9% |
| Valuation | |||||
| P/E | 38.06 | 38.06 | 24.95 | 34.18 | 39.31 |
| EV/EBITDA | 23.69 | 23.69 | 15.39 | 21.19 | 26.25 |
| P/B | 4.80 | 4.80 | 3.47 | 4.40 | 5.48 |
| Growth & Yield | |||||
| Revenue Growth | 9.0% | 9.0% | 17.1% | 14.6% | — |
| EPS Growth | 11.0% | 11.0% | 17.2% | 0.0% | — |
| Dividend Yield | 1.2% | 1.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
45.8%
EPS terminal req.
$3.75
Spread vs growth
-34.8%
5Y implied EPS CAGR
30.3%
EPS terminal req.
$4.54
Spread vs growth
-19.2%
10Y implied EPS CAGR
19.7%
EPS terminal req.
$7.31
Spread vs growth
-8.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+34.8%
Start / end P/E
29.0x → 34.9x
EPS bridge
1.09 → 1.21
Residual
+2.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.